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measurement of sd-LDL-C will be of more use than LDL-C as a surrogate maker
to determine the severity of CHD.
516 FENOFIBRATE REDUCES C-REACTIVE PROTEIN IN NON-OBESE
HYPERTRIGLYCERIDEMIC PATIENTS WITH HIGH RISKS
C.J. Kim1, M.-A. Kim2. 1Chung-Ang University, 2Seoul National University
Boramae Hospital, Seoul, Republic of Korea
Objective:We investigated the effect of fenoﬁbrate on C-reactive protein (CRP)
and variables determining changes.
Methods: This case-control study enrolled 280 hypertriglyceridemic patients
who were managed either with 200mg of fenoﬁbrate (Fenoﬁbrate group,
n = 140) or with general measures (Control group, n = 140). CRP levels were
measured before and after 2 months of therapy.
Results: CRP decreased in both fenoﬁbrate (p = 0.003) and control (p = 0.048)
groups. Changes in CRP were not different between the two groups
(−0.24±1.56 versus −0.14±1.69mg/dL, p = 0.27) and were associated
with baseline CRP levels (r = −0.47, p = 0.000). In patients with baseline
CRP 1mg/dL, CRP also decreased in both groups (p = 0.000 and p = 0.001
respectively), however, more in the fenoﬁbrate group than in the control group
(−0.79±1.90 versus −0.66±1.77mg/L, p = 0.025). The reduction of CRP was
associated with higher baseline CRP (r = −0.29, p = 0.001), lower body mass
index (r = 0.23, p = 0.007), and fenoﬁbrate therapy (r = 0.19, p = 0.025). CRP
decreased more in the fenoﬁbrate group than in the control group in patients
with body mass index 26 kg/m2 with borderline signiﬁcance (−1.21±1.82
versus −0.89±1.92mg/dL, p = 0.097). In patients with high density lipoprotein-
cholesterol <40mg/dL, only fenoﬁbrate group reduced CRP (p = 0.006).
Conclusions: Fenoﬁbrate reduced CRP in non-obese hypertriglyceridemic
patients with high CRP and/or low high density lipoprotein-cholesterol. This
ﬁnding suggests that fenoﬁbrate may have anti-inﬂammatory effect in selected
patients with high risks.
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Background and Aims: The major adipocytokines, leptin and adiponectin, play
important roles in energy homeostasis and the development of atherosclerosis.
Circulating leptin increases and adiponectin decreases in proportion to the
degree of adiposity. The leptin:adiponectin ratio (LAR) has been proposed as a
biomarker for atherosclerosis in obese type 2 diabetic patients. We examined
correlation of the LAR with insulin resistance-related factors in apparently
healthy subjects.
Methods: We recruited 300 Japanese men who underwent health checkups.
The participants were classiﬁed into three groups based on a 75-g OGTT: 194
with normal glucose tolerance, 91 with impaired fasting glucose and/or impaired
glucose tolerance and 15 with diabetes mellitus. Serum leptin and adiponectin
concentrations were measured using ELISA, and the LAR was calculated.
Results: No signiﬁcant differences in the LAR were detected among the
three groups. In total subjects, there was an inverse correlation between
leptin and adiponectin concentrations (r = −0.232, p < 0.001). The LAR was
highly correlated with BMI (r = 0.551, p < 0.001), waist circumference (r = 0.534,
p < 0.001), fasting serum insulin (r = 0.610, p < 0.001), the HOMA of insulin
resistance (HOMA-R) (r = 0.589, p < 0.001). The LAR was also positively
correlated with non-HDL-cholesterol, creatinine, ALT, CRP concentrations, and
negatively with age and HDL-cholesterol concentrations. Multiple regression
analysis showed that the LAR was independently associated with HOMA-R,
adiposity, age, triglycerides and CRP concentrations.
Conclusions: The LAR was closely associated with adiposity, insulin resistance
and an atherogenic lipid proﬁle in Japanese men. The data suggest that the
LAR is a useful biomarker of obesity-related insulin resistance.
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The Azores Islands have the highest standardized mortality rate for
cardiovascular diseases (CVD) as compared to mainland Portugal. Plasma
aminothiols, such as Hcy, Cys, Cys-Gly and GSH, which are metabolically
interrelated, play an important role in determining the redox status of cell
environment. The aim of this study was to evaluate the plasma aminothiol
proﬁle (PAP), some of its major determinants (plasma folate, vitamin-B12 and
vitamin-B6 concentrations and serum g-GT activity), as well as its relationship
with serum lipid proﬁle, in apparently healthy subjects, all born and living in the
Azores archipelago.
Participants in this study (191 women and 142 men, aged 20 to 60 years) were
split in two groups: one with a normal and another with an altered PAP (at least
one aminothiol concentration out of reference range). Plasma aminothiols and
vitamin-B6 were quantiﬁed by HPLC. The other parameters were determined
by commercial kits.
76% of the participants had an altered PAP, mainly due to low GSH levels
(<1.5 mM). That proﬁle was worse in male gender, in older or hyperlipidemic
subjects or in those with high g-GT activity. Older subjects or hyperlipidemics
showed decreased GSH and increased Cys levels and serum g-GT activity, as
compared to the respective counterparts. Hyperhomocysteinemia was present
in 10% of participants, where only 33% had B-vitamin deﬁciencies.
An altered PAP reﬂects a pro-oxidant status, thus favoring atherogenesis and
consequent CVD. Since subjects were apparently healthy, an altered PAP,
namely originated by low GSH levels, can constitute an early marker of
atherosclerosis.
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Objective: To determine the risk factors associated with subclinical coronary
atherosclerosis (CA) assessed by coronary computed tomographic angiography
(CTA).
Methods: From July 2004 to December 2008, 550 consecutive asymptomatic
subjects without history of coronary artery disease received contrast-enhanced
coronary CTA. Recognition of MetS was based on the ethnicity-modiﬁed
National Cholesterol Educational Program Adult Treatment Panel III (NCEP
ATP-III) criteria. Any presence of coronary artery calciﬁcation (CAC) or the
presence of noncalciﬁed plaques within the proximal third major coronary artery
segment(s) with zero CAC was deﬁned as presence of CA.
Results: 38% (209/550) of all subjects met ethnicity-modiﬁed NCEP ATP-III
MetS criteria. In addition to the clustering of multiple conventional cardiovascular
risk factors in MetSyn subjects, MetSyn was independently associated with
subclinical CA in multivariable analysis. (OR = 3.40, 95%CI 2.34 to −4.96,
P < 0.001). Multivariable logistic regression analysis for risk factors association
with subclinical CA revealed that fasting blood glucose 6.11mmol/L/
diagnosis of diabetes mellitus was an independent indicator of subclincial
CA in non-MetSyn subjects (OR = 1.40, 95%CI 1.08 to −1.82, P < 0.05) while
TC/HDL-C >4.2% was an independent indicator of subclinical CA in MetSyn
subjects (OR = 4.44, 95%CI 1.93 to −10.20, P < 0.001).
Conclusions: Risk factors of subclinical CA in coronary CTA are different
between subjects with and without MetSy deﬁned by ethnicity-modiﬁed NCEP
ATP-III. Fasting blood glucose/diagnosis of diabetes mellitus in non-MetSyn and
TC/HDL-C in MetSyn are independent indicator associated with subclinical CA
by coronary CTA study.
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Objectives: Increased urinary levels of 11-dehydrothromboxane B2 (TxB2)
is one of the suggested markers for aspirin resistance and are linked
with increased risk of cardiovascular events. We assessed hypothesis that
polymorphisms of cyclooxygenase-1 (COX-1) may affect periprocedural efﬁcacy
of aspirin in patients undergoing percutaneous coronary intervention (PCI).
Methods: We studied 313 patients who underwent PCI with drug-eluting stent
and recieved 100mg of aspirin for at least 10 previous days. Levels of TxB2 and
creatinine of ﬁrst morning urine of the following day after PCI were measured.
A promoter polymorphism (−707A>G; rs10306114) and a non-synonymous
coding variation (10742C>A; rs5789) were analysed.
Results: The frequency of genotypes was following: 89.8% AA (n = 281) and
10.2% AG (n = 32) for −707A>G, and 98.4% CC (n = 308) and 1.6% CA (n = 5)
for 10742C>A polymorphism. Median TxB/Cr values were insigniﬁcantly higher
in carriers of −707G allele, compared to AA genotype: 142 (496–1727 496–
1727) pg/mg vs. 816 (440–2815 440–2815) pg/mg (p = 0.298). No difference
was found for CA and CC genotypes: 698 (493–1772 493–1772) pg/mg vs. 869
(535–1749 535–1749) pg/mg (p = 0.881). In subgroup analysis, acute patients
(n = 46, 14.7%) had higher TxB/Cr (p = 0.031) than patients with scheduled PCI
(n = 267, 85.3%): 792 (469–1768 469–1768) and 1280 (663–2050). Diabetics
had higher TxB/Cr (p = 0.023): 790 (461–790) vs 1148 (597–1148 597–1148).
